Abstract P035 – Table 1.  INSTI resistance developed after failure on an INSTI‐based regimen.
Study	Country	Population	Age range (years)	INSTI used	Total on INSTI (n)	Treatment failure on INSTI (n)	Treatment failure on INSTI [% (95% CI)]	INSTI resistance following failure (n)	INSTI resistance following failure [% (95% CI)]
Clinical trials
IMPAACT P1066 [1]	Multinational	ART‐experienced, viremic	4 weeks to 18	RAL	122	60	49 (40 to 58)	19	16 (10 to 23)
GS‐US‐292‐0106 [2]	Multinational	ART‐experienced, suppressed	6 to 11	EVG	23	0	0 (0 to 15)	0	0 (0 to 15)
GS‐US‐292‐0106 [3]	Multinational	ART‐naive	12 to 18	EVG	50	3	6 (1 to 17)	0	0 (0 to 7)
GS‐US‐236‐0112 [4]	Multinational	ART‐naive	12 to 17	EVG	21	2	10 (1 to 30)	0	0 (0 to 16)
IMPAACT P1093 [5]	Multinational	ART‐naive and ART‐experienced	4 weeks to 17	DTG	142	36	25 (18 to 33)	8	6 (2 to 11)
ODYSSEY [6]	Multinational	ART‐naive and ART‐experienced, viremic	4 weeks to 17	DTG	350	47	13 (10 to 17)	4	1 (0 to 3)
SMILE PENTA‐17 [7]	Multinational	ART‐experienced, suppressed	6 to 18	DTGa	158	8	5 (2 to 10)	0	0 (0 to 2)
GS‐US‐380‐1474 [8]	Multinational	ART‐experienced, suppressed	6 to 17	BIC	100	2	2 (0 to 7)	0	0 (0 to 4)
Non‐interventional studies
Abo et al, 2019 [9]	United Kingdom	ART‐naive and ART‐experienced	0 to 17	DTG/ RAL/ EVG	29/ 21/ 6	8b	14 (6 to 26)	1b	2 (0 to 10)
Levy et al, 2020 [10]	United States	ART‐experienced	0 to 24	DTG	78	72c	51 (43 to 60)	0	0 (0 to 5)
				RAL	11			1	9 (0 to 41)
				EVG	52			1	2 (0 to 10)
Briz et al, 2012 [11]	Spain	ART‐experienced, viremic	6 to 18	RAL	19	2d	11 (1 to 33)	0	0 (0 to 18)
Patten et al, 2020 [12]	Multinational	ART‐experienced, viremic	0 to 17	RAL	62	24e	39 (27 to 52)	4f	6 (2 to 16)
Steegen et al, 2019 [13]	South Africa	ART‐experienced	0 to 17	RAL	7g	7	100 (59 to 100)	2	29 (4 to 71)
Briand et al, 2017 [14]	France	ART‐naive and ART‐experienced	12 to 17	DTG	50	17	34 (21 to 49)	0	0 (0 to 7)
Frange et al, 2019 [15]	France	ART‐naive and ART‐experienced	5 to 25	DTG	109	22	20 (13 to 29)	0	0 (0 to 3)
Frange et al, 2021 [16]	France	ART‐naive and ART‐experienced	6 to 18	DTG	134	43	32 (24 to 41)	1	1 (0 to 4)

^aOne hundred and fifty‐three took DTG+DRV/r, five took EVG+DRV/r;

^baggregated results for all INSTI‐based regimens reported;

^caggregated results for all INSTI‐based regimens reported for virologic outcomes; virologic failure defined as: 55/70 individuals not suppressed at baseline never achieved suppression or had viral rebound after suppression; 17/35 suppressed at baseline did not maintain suppression through follow‐up;

^dvirologic failure defined as: 2/19 never achieved viral load <400 copies/mL during follow‐up (non‐responders);

^evirologic failure defined as: 16/62 never achieved viral load <400 copies/mL during follow‐up and 8/62 experienced virologic rebound ≥1000 copies/mL after achieving suppression;

^ffour discontinuations were attributed to virologic failure, immunologic failure, or resistance ‐ no additional details provided;

^gstudy looked at samples from individuals currently failing INSTI‐based regimens; there were seven samples from individuals <18 years old.